Special Issue "Noncoding RNAs in Renal Cell Carcinoma Landscape"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".

Deadline for manuscript submissions: 28 February 2021.

Special Issue Editors

Dr. Ana Luísa Teixeira

Guest Editor
Molecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal
Interests: molecular oncology; molecular biomarkers (genetic polymorphisms, RNAs and non-coding RNAs); extracellular vesicles; urological cancers
Dr. Francisca Dias

Guest Editor
Molecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal
Interests: molecular oncology; molecular biomarkers (genetic polymorphisms, RNAs and non-coding RNAs); extracellular vesicles; urological cancers
Prof. Dr. Rui Medeiros
SciProfiles
Guest Editor
Molecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal
Interests: molecular oncology; precision medicine, pharmacogenomics; virology and patophysiology (prognostic biomarkers,; predictive biomarkers,; miRNA,; genetic polymorphism, and; viral nucleic acids)
Special Issues and Collections in MDPI journals

Special Issue Information

Dear colleagues,

In recent years, accumulating evidence has highlighted that noncoding RNAs are key regulators of gene expression in the development of several diseases, including cancer.

In fact, it is now known that approximately 90% of the human genome can be transcribed into RNA transcripts, which opens the door for innumerous possibilities that can allow for a better understanding of the regulatory mechanisms behind cancer development. The majority of RNAs transcripts are noncoding RNAs, which include housekeeping ncRNAs such as transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), and snoRNAs as well as regulatory ncRNAs including microRNAs (miRNAs), small interfering RNAs (siRNAs), small nuclear RNAs (snRNAs), circular RNAs, and long noncoding RNAs (lncRNAs).

Recent genomic data have demonstrated high molecular heterogeneity in renal cell carcinoma (RCC) which may be an explanation for the variable clinical outcomes in this type of cancer. Despite the significant progress in the understanding of the molecular biology and pathology of RCC, the prediction of outcomes for individual patients still remains a challenge in the field.

This Special Issue aims to provide a comprehensive overview of the impact of noncoding RNAs on RCC development and progression by considering their association with key features of RCC, namely microenvironment, drug resistance, metabolism, angiogenesis, metastatic process, and immune response.

We encourage studies that suggest noncoding RNAs as potential biomarkers for RCC development, progression, and therapy response.

Prof. Dr. Rui Medeiros
Dr. Ana Luísa Teixeira
Dr. Francisca Dias
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Extracellular Vesicles Enriched in hsa-miR-301a-3p and hsa-miR-1293 Dynamics in Clear Cell Renal Cell Carcinoma Patients: Potential Biomarkers of Metastatic Disease
Cancers 2020, 12(6), 1450; https://doi.org/10.3390/cancers12061450 - 02 Jun 2020
Cited by 1
Abstract
Clear cell renal cell carcinoma (ccRCC) is the most aggressive subtype of kidney cancer and up to 40% of patients submitted to surgery with a curative intent will relapse. Thus, the aim of this study was to analyze the applicability of an Extracellular [...] Read more.
Clear cell renal cell carcinoma (ccRCC) is the most aggressive subtype of kidney cancer and up to 40% of patients submitted to surgery with a curative intent will relapse. Thus, the aim of this study was to analyze the applicability of an Extracellular vesicle (EV) derived miRNA profile as potential prognosis biomarkers in ccRCC patients. We analyzed a nine-miRNA profile in plasma EVs from 32 ccRCC patients with localized disease (before and after surgery) and in 37 patients with metastatic disease. We observed that the levels of EV-derived hsa-miR-25-3p, hsa-miR-126-5p, hsa-miR-200c-3p, and hsa-miR-301a-3p decreased after surgery, whereas hsa-miR-1293 EV-levels increased. Furthermore, metastatic patients presented higher levels of hsa-miR-301a-3p and lower levels of hsa-miR-1293 when compared to patients with localized disease after surgery. Functional enrichment analysis of the targets of the four miRNAs that decreased after surgery resulted in an enrichment of terms related to cell cycle, proliferation, and metabolism, suggesting that EV-miRNA enrichment in the presence of the tumor could represent an epigenetic mechanism to sustain tumor development. Taken together, these results suggest that EVs content varies depending on the presence or absence of the disease and that an increase of EV-derived hsa-miR-301a-3p, and decrease of EV-derived hsa-miR-1293, may be potential biomarkers of metastatic ccRCC. Full article
(This article belongs to the Special Issue Noncoding RNAs in Renal Cell Carcinoma Landscape)
Show Figures

Figure 1

Back to TopTop